73
Participants
Start Date
March 10, 2017
Primary Completion Date
April 13, 2023
Study Completion Date
April 13, 2023
MEN1703
MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
Northside Hospital, Atlanta
Vanderbilt Ingram Cancer Center, Nashville
Cleveland Clinic, Taussig Cancer Institute, Cleveland
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
MD Anderson Cancer Center, Houston
Oregon Health and Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Istituto Clinico Humanitas, Milan
ASST Monza - Ospedale San Gerardo, Monza
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Oddzial Hematologii z Pododdzialem Chemioterapi, Lodz
Institute of Haematology and Blood Transfusion, Warsaw
Institut Català d'Oncologia, Badalona
Hospital 12 de Octubre, Madrid
Hospital Universitari i Politecnic La Fe, Valencia
Lead Sponsor
Collaborators (2)
Medpace, Inc.
INDUSTRY
Theradex
INDUSTRY
Menarini Group
INDUSTRY